This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary MEK Therapeutic Antibody Development
Background of MEK
BioVenic provides comprehensive veterinary MEK therapeutic antibody development services covering the complete antibody development workflow, including preparation, purification, characterization and validation. We support the generation of high-quality veterinary MEK therapeutic antibodies and help researchers investigate their therapeutic potential for cancers in companion animals. Serving as a key component in signal transduction, MEK plays a vital role in the initiation and progression of multiple cancers affecting companion animals. Accordingly, therapeutic antibodies targeting MEK represent a promising strategy for cancer treatment in companion animals.
Background of MEK
| Full Name | Mitogen-activated protein kinase kinase |
|---|---|
| Aliases | MAP2K, MAPKK. |
| Target Profile | MEK is a key enzyme in cellular signal transduction, part of the MAPK signaling pathway. MEK specifically phosphorylates and activates ERK, thereby regulating cell growth, differentiation, proliferation, and survival. |
MoA of MEK
The RAS/RAF/MEK pathway is often activated by various extracellular stimuli, growth factors, hormones, cytokines, and environmental stresses. MEK, positioned in the middle stage of the ERK signaling pathway, is activated by upstream kinases and activates ERK by adding phosphate groups to specific amino acid residues of ERK. ERK then moves into the cell nucleus, influencing the expression of specific genes involved in cell cycle regulation, differentiation, cell survival, and apoptosis. Mutations in MEK are not common in solid tumors, but when genes encoding RAS or BRAF mutate or amplify, they activate ERK signaling through MEK, making MEK an attractive target for anti-cancer drug development.
Fig.1 Schematic diagram of MEK activation in cancer.1,2
Application in Veterinary Therapeutics
Canine prostate cancer, a malignant tumor, often presents the BRAF V595E mutation, analogous to the BRAF V600E mutation in humans. Activating BRAF mutations are considered oncogenic drivers, and blocking ERK phosphorylation could be an effective therapeutic target for tumors with BRAF mutations. Thus, using veterinary therapeutic MEK antibodies to inhibit MEK activity can modulate signaling pathways, disrupting tumor cell proliferation and survival, thereby providing an effective means to control or slow down cancer progression.
Veterinary MEK Therapeutic Antibody Development Services
Abnormal activation of MEK is often associated with malignant transformation and resistance to treatment, making MEK an attractive target for developing novel anti-cancer therapies. BioVenic offers comprehensive veterinary MEK therapeutic antibody development services, employing technologies such as hybridoma, single B cell, and phage display for antibody preparation. Our services also include antibody characterization and engineering, covering structural and functional characterization, affinity maturation, and the development of species-specific antibodies, enhancing the safety and therapeutic efficacy of antibody samples for companion animals.
Please click the link below for more information about our veterinary MEK therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic's one-stop veterinary therapeutic antibody development services encompass a range of immunogens, immunization animals, antibody preparation techniques, and validation methods, customizable to individual needs.
Considering the immunogenicity, affinity, and half-life of veterinary therapeutic antibodies, we offer antibody engineering services to enhance the potential therapeutic effect of antibody samples and reduce adverse reactions due to immunogenicity.
Our team implements strict quality control throughout the development process of veterinary therapeutic antibodies, maintaining high purity, safety, and batch consistency of antibody samples.
Frequently Asked Questions
What central regulatory role does MEK play in the classic RAS/RAF/ERK tumor signaling axis?
MEK is the core dual-specific kinase positioned in the middle of the RAS/RAF/ERK cascade. Activated upstream BRAF phosphorylates MEK, and activated MEK further phosphorylates ERK. Activated ERK enters the nucleus to drive the transcription of genes that control tumor cell proliferation, differentiation and survival, serving as an indispensable signal relay node for oncogenic pathways.
Which companion animal tumor is the primary research model for MEK-targeted antibody therapy, and what key mutation drives its signaling activation?
Canine prostate cancer is the core research object. This tumor frequently carries the BRAF V595E mutation, which is functionally equivalent to human BRAF V600E oncogenic mutation. Mutant BRAF continuously activates downstream MEK-ERK signaling to sustain malignant proliferation of prostate tumor cells.
What anti-tumor mechanism can anti-MEK therapeutic antibodies exert on BRAF-mutated canine tumors?
Anti-MEK antibodies specifically bind and block MEK kinase activity, cutting off the phosphorylation cascade towards ERK. This shuts down downstream oncogenic gene transcription, restraining tumor cell cycle progression, inhibiting cancer cell proliferation and slowing the progression of BRAF-driven canine malignant lesions.
What full-spectrum antibody engineering services do you provide for canine/feline MEK therapeutic antibodies?
We deliver multiple optimization strategies including affinity maturation, CDR grafting, chimeric antibody construction and full caninization/felinization transformation. These modifications reduce heterologous protein components to lower immune rejection risk in pets, while retaining high binding activity against animal-derived MEK targets.
What complete functional validation items are included in our MEK antibody post-screening quality control workflow?
After antibody preparation and purification, we conduct cell-level pathway activity detection to verify the antibody's ability to suppress ERK phosphorylation, combined with purity testing and stability identification, providing complete functional data to support preclinical tumor intervention research in companion animals.
Partner with BioVenic
MEK-mediated signaling is closely associated with the onset and progression of companion animal tumors. BioVenic offers veterinary MEK therapeutic antibody development services, providing support throughout the development process. If you have a project requirement for the development, please contact us for more information!
References
- Adamopoulos, Christos, Donatella Delle Cave, and Athanasios G. Papavassiliou. "Inhibition of the RAF/MEK/ERK signaling cascade in pancreatic cancer: recent advances and future perspectives." International Journal of Molecular Sciences 25.3 (2024): 1631.
- Image retrieved from Figure 2 " RAF/MEK/ERK pathway inhibitors and combination therapies under clinical evaluation for pancreatic cancer." Adamopoulos, Christos, et al., 2024, used under [CC BY 3.0], the image title was changed to "Schematic diagram of MEK activation in cancer."